# Imunon (IMNN) — News

IMNN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/imnn/news

## Recent headlines

- [Imunon - Enters exchange agreement with Streeterville Capital on Sept 28, 2026 - SEC filing](https://www.ainvest.com/news/imunon-enters-exchange-agreement-streeterville-capital-sept-28-2026-sec-filing-2609) — AInvest Wire, Sep 29, 2026
  Imunon, Inc. (NASDAQ: IMNN) has entered into a complex securities exchange agreement with Streeterville Capital, LLC, as disclosed in a recent SEC filing dated September 28, 2026. Under the terms of the agreement, the company issued 250 shares of Series A Preferred Stock, secured promissory notes…
- [Imunon - Converts $1.20 mln of debt into Series B preferred stock](https://www.ainvest.com/news/imunon-converts-1-20-mln-debt-series-preferred-stock-2609) — AInvest Wire, Sep 29, 2026
  Imunon, Inc. (NASDAQ: IMNN) has announced the conversion of $1.20 million of its outstanding debt into Series B preferred stock, marking a strategic move to restructure its capital and reduce immediate financial obligations. The conversion is part of a broader agreement with Streeterville Capital,…
- [Imunon - Targets Ovation 3 enrollment completion in Q1 2029](https://www.ainvest.com/news/imunon-targets-ovation-3-enrollment-completion-q1-2029-2609) — AInvest Wire, Sep 24, 2026
  Imunon Inc. has outlined its strategic focus on advancing its Phase 3 clinical trial, Ovation 3, with a target to complete enrollment by the first quarter of 2029. The company has reported strong momentum in patient recruitment , reflecting ongoing progress in its clinical development pipeline.…
- [Imunon makes the frontline case for phase 3 IMNN-001 study: 14.7-month OS signal, historical IL-12 safety barriers overcome, enrolling ahead of plan](https://www.ainvest.com/news/imunon-frontline-case-phase-3-imnn-001-study-14-7-month-os-signal-historical-il-12-safety-barriers-overcome-enrolling-plan-2609) — AInvest Wire, Sep 24, 2026
- [Imunon - IDMC recommends phase 2 mrd study continue without modification after safety review](https://www.ainvest.com/news/imunon-idmc-recommends-phase-2-mrd-study-continue-modification-safety-review-2609) — AInvest Wire, Sep 22, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).